Reuters logo
BRIEF-Geneuro and Servier announce 6-month results from CHANGE-MS Phase 2b study in multiple sclerosis
August 28, 2017 / 5:49 AM / 22 days ago

BRIEF-Geneuro and Servier announce 6-month results from CHANGE-MS Phase 2b study in multiple sclerosis

Aug 28 (Reuters) - GENEURO SA:

* GENEURO AND SERVIER ANNOUNCE SIX-MONTH RESULTS FROM CHANGE-MS PHASE 2B STUDY IN MULTIPLE SCLEROSIS

* GNBAC1 IS WELL TOLERATED; ANTI-INFLAMMATORY EFFECT NOT DEMONSTRATED AT 6 MONTHS

* ANALYSIS OF FULL 12-MONTH PHASE 2B DATA EXPECTED 1Q18 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below